Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations

Journal of Infectious Diseases

Volumn 205, Issue 12, 2012, Pages 1821-1829

  Kunz, Anjali N ^a,b   Begum, Afrin A ^a   Wu, Hong ^a   D'Ambrozio, Jonathan A ^a   Robinson, James M ^a   Shafer, William M ^c,d   Bash, Margaret C ^e   Jerse, Ann E ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ERYTHROMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GONORRHEA; GYRA GENE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEISSERIA GONORRHOEAE; NONHUMAN; PARC GENE; PRIORITY JOURNAL; PROMOTER REGION;

ANIMALS; ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GONORRHEA; MACROLIDES; MICE; MICE, INBRED BALB C; MUTATION; NEISSERIA GONORRHOEAE; VIRULENCE;

EID: 84861553437     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis277     Document Type: Article

References (48)

1. Hook EW, Handsfield HH. Gonococcal infections in the adult. In: Holmes KK, Mardh PA, Sparling PF, et al., eds. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill; 1999:451-66.
2. Workowski KA, Berman S. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1-110.
3. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3-17.
4. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55:3538-45.
5. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1-94.
6. Chen FJ, Lo HJ. Molecular mechanisms of fluoroquinolone resistance. J Microbiol Immunol Infect 2003; 36:1-9.
7. Tapsall JW. Antibiotic resistance in Neisseria gonorrhoeae. Clin Infect Dis 2005; 41(Suppl 4):S263-8.
8. Trees DL, Sandul AL, Neal SW, Higa H, Knapp JS. Molecular epidemiology of Neisseria gonorrhoeae exhibiting decreased susceptibility and resistance to ciprofloxacin in Hawaii, 1991-1999. Sex Transm Dis 2001; 28:309-14.
9. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2007 supplement, Gonoccocal Isolate Surveillance Project (GISP) annual report 2007. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2009:1-110.
10. Belland RJ, Morrison SG, Ison C, Huang WM. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol 1994; 14:371-80.
11. Deguchi T, Saito I, Tanaka M, et al. Fluoroquinolone treatment failure in gonorrhea. Emergence of a Neisseria gonorrhoeae strain with enhanced resistance to fluoroquinolones. Sex Transm Dis 1997; 24:247-50.
12. Tanaka M, Nakayama H, Huruya K, et al. Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype. Int J Antimicrob Agents 2006; 27:20-6.
13. Trees DL, Sandul AL, Peto-Mesola V, et al. Alterations within the quinolone resistance-determining regions of GyrA and ParC of Neisseria gonorrhoeae isolated in the Far East and the United States. Int J Antimicrob Agents 1999; 12:325-32.
14. Schulz zur Wiesch P, Engelstadter J, Bonhoeffer S. Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicrob Agents Chemother 2010; 54:2085-95.
15. Ding Y, Onodera Y, Lee JC, Hooper DC. NorB, an efflux pump in Staphylococcus aureus strain MW2, contributes to bacterial fitness in abscesses. J Bacteriol 2008; 190:7123-9.
16. Luo N, Pereira S, Sahin O, et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Natl Acad Sci USA 2005; 102:541-6.
17. Marcusson LL, Frimodt-Moller N, Hughes D. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 2009; 5:e1000541.
18. Warner DM, Shafer WM, Jerse AE. Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol Microbiol 2008; 70:462-78.
19. Zhang Q, Sahin O, McDermott PF, Payot S. Fitness of antimicrobialresistant Campylobacter and Salmonella. Microbes Infect 2006; 8:1972-8.
20. Andersson DI. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 2006; 9:461-5.
21. Hagman KE, Pan W, Spratt BG, Balthazar JT, Judd RC, Shafer WM. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 1995; 141(Pt 3):611-22.
22. Jerse AE, Sharma ND, Simms AN, Crow ET, Snyder LA, Shafer WM. A gonococcal efflux pump system enhances bacterial survival in a female mouse model of genital tract infection. Infect Immun 2003; 71:5576-82.
23. Shafer WM, Qu X, Waring AJ, Lehrer RI. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci USA 1998; 95:1829-33.
24. Hagman KE, Shafer WM. Transcriptional control of the mtr efflux system of Neisseria gonorrhoeae. J Bacteriol 1995; 177:4162-5.
25. Giles JA, Falconio J, Yuenger JD, Zenilman JM, Dan M, Bash MC. Quinolone resistance-determining region mutations and por type of Neisseria gonorrhoeae isolates: resistance surveillance and typing by molecular methodologies. J Infect Dis 2004; 189:2085-93.
26. Gunn JS, Stein DC. Use of a non-selective transformation technique to construct a multiply restriction/modification-deficient mutant of Neisseria gonorrhoeae. Mol Gen Genet 1996; 251:509-17.
27. Warner DM, Folster JP, Shafer WM, Jerse AE. Regulation of the MtrC-MtrD-MtrE efflux-pump system modulates the in vivo fitness of Neisseria gonorrhoeae. J Infect Dis 2007; 196:1804-12.
28. Jerse AE. Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice. Infect Immun 1999; 67:5699-708.
29. Centers for Disease Control and Prevention. Agar dilution antimicrobial susceptibility testing. http://www.cdc.gov/STD/Gonorrhea/lab/agar.htm. Accessed June 1, 2009.
30. Knapp JS, Hale JA, Neal SW, Wintersheid K, Rice RJ, Whittington WL. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin. Antimicrob Agents Chemother 1995; 39:2442-5.
31. Wu H, Jerse AE. Alpha-2,3-sialyltransferase enhances Neisseria gonorrhoeae survival during experimental murine genital tract infection. Infect Immun 2006; 74:4094-103.
32. Song W, Condron S, Mocca BT, et al. Local and humoral immune responses against primary and repeat Neisseria gonorrhoeae genital tract infections of 17β-estradiol-treated mice. Vaccine 2008; 26:5741-51.
33. Balsalobre L, Ferrandiz MJ, Linares J, Tubau F, de la Campa AG. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47:2072-81.
34. Komp Lindgren P, Marcusson LL, Sandvang D, Frimodt-Moller N, Hughes D. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob Agents Chemother 2005; 49:2343-51.
35. O'Regan E, Quinn T, Frye JG, et al. Fitness costs and stability of a high-level ciprofloxacin resistance phenotype in Salmonella enterica serotype enteritidis: reduced infectivity associated with decreased expression of Salmonella pathogenicity island 1 genes. Antimicrob Agents Chemother 2010; 54:367-74.
36. Pope CF, Gillespie SH, Pratten JR, McHugh TD. Fluoroquinoloneresistant mutants of Burkholderia cepacia. Antimicrob Agents Chemother 2008; 52:1201-3.
37. Rozen DE, McGee L, Levin BR, Klugman KP. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51:412-6.
38. Vickers AA, O'Neill AJ, Chopra I. Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies. J Antimicrob Chemother 2007; 60:269-73.
39. Jerse AE, Wu H, Packiam M, Vonck RA, Begum AA, Garvin LE. Estradiol-treated female mice as surrogate hosts for Neisseria gonorrhoeae genital tract infections. Front Microbiol 2011; 2:107.
40. Allen VG, Farrell DJ, Rebbapragada A, et al. Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada. Antimicrob Agents Chemother 2011; 55: 703-12.
41. Dewi BE, Akira S, Hayashi H, Ba-Thein W. High occurrence of simultaneous mutations in target enzymes and MtrRCDE efflux system in quinolone-resistant Neisseria gonorrhoeae. Sex Transm Dis 2004; 31:353-9.
42. Vorobieva V, Firsova N, Ababkova T, et al. Antibiotic susceptibility of Neisseria gonorrhoeae in Arkhangelsk, Russia. Sex Transm Infect 2007; 83:133-5.
43. Bjorkholm B, Sjolund M, Falk PG, Berg OG, Engstrand L, Andersson DI. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc Natl Acad Sci USA 2001; 98:14607-12.
44. Macvanin M, Bjorkman J, Eriksson S, Rhen M, Andersson DI, Hughes D. Fusidic acid-resistant mutants of Salmonella enterica serovar Typhimurium with low fitness in vivo are defective in RpoS induction. Antimicrob Agents Chemother 2003; 47:3743-9.
45. Nagaev I, Bjorkman J, Andersson DI, Hughes D. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol 2001; 40:433-9.
46. Trzcinski K, Thompson CM, Gilbey AM, Dowson CG, Lipsitch M. Incremental increase in fitness cost with increased beta-lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model. J Infect Dis 2006; 193:1296-303.
47. Yang Y, Liao M, Gu WM, et al. Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai. J Antimicrob Chemother 2006; 58:868-72.
48. Ruiz J, Jurado A, Garcia-Mendez E, et al. Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones. J Antimicrob Chemother 2001; 48:545-8.